This commercial partnership can benefit all stem cell companies, legitimising stem cell science and technology in both the general public's and regulators' (plural) eyes. Other companies will benefit from this, some people are too short-sighted to see this.
@Sector is (allegedly) a Top 20 holder in CYP - of course he doesn't want to see the alternative view. This dude is wearing out keyboards on the CYP threads re MSB...
Today's announcement is very positive for MSB, and there are some serious SP catalysts potentially just around the corner.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-320
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |